Literature DB >> 9630372

The diagnosis of Clostridium difficile-associated disease.

J S Brazier1.   

Abstract

There are well-documented risk factors associated with the development of antibiotic-associated diarrhoea; knowledge of these and of the typical signs and symptoms should alert the clinician to the possibility of Clostridium difficile-associated diarrhoea (CDAD). It is therefore common practice in large general hospitals for clinicians to request, and for laboratories to include, investigations for C. difficile on in-patient stool specimens to confirm a diagnosis of CDAD. The laboratory methods used to investigate for CDAD are divided into two main categories: those that are aimed at detecting the presence of C. difficile or its products, and those that detect either of its two major toxins, A (enterotoxin) and B (cytotoxin). Within each of these broad strategies there are various rationales which are reviewed here.

Entities:  

Mesh:

Year:  1998        PMID: 9630372     DOI: 10.1093/jac/41.suppl_3.29

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

Review 1.  Update on gastrointestinal infections: Clostridium difficile and other bugs.

Authors:  C M Surawicz
Journal:  Curr Gastroenterol Rep       Date:  1999-10

2.  A survey of stool culturing practices for vibrio species at clinical laboratories in Gulf Coast states.

Authors:  N N Marano; N A Daniels; A N Easton; A McShan; B Ray; J G Wells; P M Griffin; F J Angulo
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of Premier Cytoclone A+B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains.

Authors:  A Lozniewski; C Rabaud; E Dotto; M Weber; F Mory
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

4.  Evaluation of a new automated homogeneous PCR assay, GenomEra C. difficile, for rapid detection of Toxigenic Clostridium difficile in fecal specimens.

Authors:  Jari J Hirvonen; Silja Mentula; Suvi-Sirkku Kaukoranta
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

5.  Laboratory detection of Clostridium difficile in piglets in Australia.

Authors:  Daniel R Knight; Michele M Squire; Thomas V Riley
Journal:  J Clin Microbiol       Date:  2014-08-13       Impact factor: 5.948

6.  Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile.

Authors:  A P Limaye; D K Turgeon; B T Cookson; T R Fritsche
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

7.  Evaluation of a chromogenic culture medium for isolation of Clostridium difficile within 24 hours.

Authors:  John D Perry; Kerry Asir; Diane Halimi; Sylvain Orenga; Joanne Dale; Michelle Payne; Ruth Carlton; Jim Evans; F Kate Gould
Journal:  J Clin Microbiol       Date:  2010-08-25       Impact factor: 5.948

8.  Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile.

Authors:  Ludovic Lemee; Anne Dhalluin; Sabrina Testelin; Marie-Andre Mattrat; Karine Maillard; Jean-François Lemeland; Jean-Louis Pons
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

9.  Performance of the TechLab C. DIFF CHEK-60 enzyme immunoassay (EIA) in combination with the C. difficile Tox A/B II EIA kit, the Triage C. difficile panel immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-associated diarrhea.

Authors:  Heather Snell; Meredith Ramos; Sue Longo; Michael John; Zafar Hussain
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

10.  Epidemiology and molecular characterization of Clostridium difficile strains from patients with diarrhea: low disease incidence and evidence of limited cross-infection in a Swedish teaching hospital.

Authors:  Bo Svenungsson; Lars G Burman; Kirsti Jalakas-Pörnull; Asa Lagergren; Johan Struwe; Thomas Akerlund
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.